John Mendelsohn Latest Insider Activity
Management EfficiencyThe company has return on total asset (ROA) of (29.17) % which means that it has lost $29.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (63.21) % meaning that it created substantial loss on money invested by shareholders.
Entity SummaryMerrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 72 people.Merrimack Pharmaceuticals (MACK) is traded on BATS Exchange in USA. It is located in Massachusetts U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Merrimack Pharmaceuticals Leadership Team
Stock Performance Indicators